-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target

Benzinga·05/08/2026 10:34:37
Listen to the news
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $53 price target.